By Frank Prenesti
Date: Monday 01 Oct 2018
(Sharecast News) - AstraZeneca said it had agreed a $200m deal with Germany's Cheplapharm Arzneimittel for the European commercial rights to Atacand and Atacand Plus heart and hypertension treatments.
Sunday share tips: AstraZeneca, Genus, 'Dogs of ... | 30-Jul-2017 | ShareCast |
AstraZeneca co-develops treatment for Alzheimer'... | 09-Dec-2016 | ShareCast |
No recent information was found.
Questor :AstraZeneca | 29-Apr-2014 | Telegraph |
Questor : AstraZeneca | 24-Jan-2014 | Telegraph |
Questor:AstraZeneca | 22-Dec-2011 | Telegraph |
Investment Column:AstraZeneca | 28-Oct-2011 | The Independent |
Investment Column: AstraZeneca | 23-Jun-2011 | The Independent |
Currency | UK Pounds |
Share Price | 10,635.00p |
Change Today | 2.16p |
% Change | 2.07 % |
52 Week High | 13,250.00p |
52 Week Low | 9,642.00p |
Volume | 438,592 |
Shares Issued | 1,264.16m |
Market Cap | £134,444m |
Strong Buy | 10 |
Buy | 14 |
Neutral | 5 |
Sell | 0 |
Strong Sell | 0 |
Total | 29 |
Time | Volume / Share Price |
16:29 | 418 @ 10,637.00p |
16:29 | 18 @ 10,640.00p |
16:29 | 46 @ 10,640.00p |
16:29 | 400 @ 10,638.00p |
16:29 | 46 @ 10,638.00p |
You are here: research